The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

The UK-US deal does not resolve every challenge – no single agreement could. But it marks a meaningful step toward restoring ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singaporean Health Sciences Authority (HSA) say the ...

RNA interference drug developer SanegeneBio leads our round-up of this week's biotech financings, with a $110 million Series ...

Drug delivery is no longer just about convenience. It’s about enabling the therapies of the future to succeed where they ...

Blood is a rich source for biomarker development, and CTCs are increasingly proving themselves to be valuable in cancer ...

Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing ...

Flow Neuroscience has secured FDA approval for its at-home brain stimulation device, the FL-100 wearable device, as a ...

Pfizer's oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive ...

The results of the lidERA trial in patients with HR-positive, HER2-negative early breast cancer – previewed last month and ...

The deal focuses on a weight-loss pill in development at YaoPharma, a GLP-1 agonist codenamed YP05002, which is currently in ...

Today, the EU Council and Parliament reached an agreement in principle on the long-awaited pharma reform package, but ...